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Abstract
Background: Carnitine has attracted scientific interest due to several health-related effects, like protection against
neurodegeneration, mitochondrial decay, and oxidative stress as well as improvement of glucose tolerance and
insulin sensitivity. The mechanisms underlying most of the health-related effects of carnitine are largely unknown.
Methods: To gain insight into mechanisms through which carnitine exerts its beneficial metabolic effects, we fed
piglets either a control or a carnitine supplemented diet, and analysed the transcriptome in the liver.
Results: Transcript profiling revealed 563 genes to be differentially expressed in liver by carnitine supplementation.
Clustering analysis of the identified genes revealed that most of the top-ranked annotation term clusters were
dealing with metabolic processes. Representative genes of these clusters which were significantly up-regulated by
carnitine were involved in cellular fatty acid uptake, fatty acid activation, fatty acid b-oxidation, glucose uptake, and
glycolysis. In contrast, genes involved in gluconeogenesis were down-regulated by carnitine. Moreover, clustering
analysis identified genes involved in the insulin signaling cascade to be significantly associated with carnitine
supplementation. Furthermore, clustering analysis revealed that biological processes dealing with
posttranscriptional RNA processing were significantly associated with carnitine supplementation.
Conclusion: The data suggest that carnitine supplementation has beneficial effects on lipid and glucose
homeostasis by inducing genes involved in fatty acid catabolism and glycolysis and repressing genes involved in
gluconeogenesis.
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Background
Carnitine (3-hydroxy-4-N, N, N-trimethylaminobutyric
acid) belongs to the class of conditionally essential
nutrients and has a number of indispensable functions
in intermediary metabolism. Carnitine is necessary for
fatty acid metabolism due to its role in the transfer of
long-chain fatty acids (acyl groups) from the cytosol
into the mitochondrial matrix for subsequent b-oxida-
tion [1]. Moreover, carnitine facilitates the transport of
peroxisomal b-oxidation products to the mitochondria,
the export accumulating acyl-groups and acts as a CoA
buffer in mammalian cells [2]. Carnitine in the body ori-
ginates from intestinal absorption from dietary sources,
especially meat, fish and dairy products [3] and enzyme
catalyzed endogenous synthesis [4], which involves five
enzymatic steps. Given that the last enzyme required for
carnitine synthesis, g-butyrobetaine hydroxylase, is only
active in liver and kidney, other tissues than liver and
kidney are dependent on the active uptake of carnitine
from blood into tissues which is catalyzed by novel
organic cation transporters (OCTN), particularly
OCTN2 which is the physiologically most important
carnitine transporter [5].
In livestock animal nutrition, supplementation with L-
carnitine has attracted great interest due to its ability to
improve performance characteristics, such as growth rate,
feed conversion ratio, protein:fat accretion [6-8]. However,
L-carnitine is also of interest for human nutrition because
recent studies indicated that L-carnitine exerts several
other effects which may be useful for the treatment of
degenerative and metabolic disorders. For instance, sup-
plementation of L-carnitine or acyl-carnitines has been
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associated with protecting against neurodegeneration [9],
age-dependent mitochondrial decay [10], and oxidative
stress [11]. In addition, L-carnitine was shown to improve
glucose tolerance and insulin sensitivity in animals as well
as in healthy and diabetic patients [12,13]. Moreover, L-
carnitine supplementation was shown to be useful for the
treatment of hepatic steatosis induced by total parenteral
nutrition in rodents [14] and nonalcoholic steatohepatitis
in humans [15,16]. Furthermore, L-carnitine was reported
to reduce hepatic inflammation and plasma levels of cyto-
kines and acute phase proteins in patients with chronic
hepatitis C [16]. The mechanisms underlying many of
these beneficial effects of L-carnitine are largely unknown.
Therefore, the present study was designed to gain insight
into mechanisms and pathways influenced by L-carnitine.
For this end, we used piglets, indicating many genetical
and physiological similarities with humans, making it an
optimal species to study the effect of L-carnitine on tran-
script profile.
We considered the liver as the target organ because it
plays a central role in whole body metabolism by regu-
lating glucose and lipid homeostasis as well as protein
synthesis. In this sense, we used liver samples taken
from a previous experiment with piglets [17] which
were fed a either a control diet with a low native carni-
tine content or a diet supplemented with 500 mg/kg
diet L-carnitine and performed genome-wide transcript
profiling in the liver of these piglets.
Methods
Animal experiment
The animal experiment was approved by the local Ani-
mal Care and Use Committee. As described recently in
more detail [17], the experiment was performed with
sixteen male crossbred pigs [(German Landrace × Large
White) × Pietrain] with an average body weight of 10 ±
1 (mean ± SD) kg. The pigs were assigned to two
groups (control group and carnitine group) and fed
experimental diets for a period of 21 days. The control
group received a basal diet with a low native carnitine
concentration (< 5 mg/kg) which was nutritionally ade-
quate for growing pigs in a body weight range between
10 and 20 kg, according to the recommendations of the
German Society for Nutrition Physiology (Gesellschaft
für Ernährungsphysiologie, 2006). The carnitine group
received the same diet supplemented with 500 mg L-
carnitine (obtained from Lohmann Animal Health, Cux-
haven, Germany) per kg. Blood was collected and
plasma obtained by centrifugation of the blood, and
liver was excised. Plasma and liver samples were imme-
diately stored at -80°C until analysis. A full description
of diet composition, feeding regime, sample collection
and carnitine analysis of diets and tissues can be found
in our recent publication [17].
Carnitine analysis
Concentrations of free carnitine, acetyl carnitine and
propionyl carnitine in liver of pigs fed either a control
diet or a diet supplemented with 500 mg/kg carnitine
for 20 days were determined by tandem mass spectro-
metry using deuterated carnitine-d3 (Larodane Fine
Chemicals, Malmö, Sweden) as internal standard as
described recently in detail [17]. Concentration of total
carnitine represents the sum of free carnitine, acetyl car-
nitine and propionyl carnitine.
RNA isolation and quality control
Total RNA was prepared from 20-30 mg of frozen liver
tissue using the RNeasy Minikit (Qiagen, Hilden, Ger-
many) according to the manufacturer’s protocol. After-
wards, the RNA concentration and purity were
estimated from the optical density at 260 and 280 nm,
respectively. The A260/280 ratio of all individual sam-
ples was 1.98 ± 0.02 (mean ± SD). The integrity of the
total RNA was checked by 1% agarose gel electrophor-
esis. RNA was judged as suitable for array hybridization
only if the samples exhibited intact bands corresponding
to the 18S and 28S ribosomal RNA subunits.
Microarray analysis
For microarray analyses, two RNA pools for each group
(control, n = 2; carnitine group, n = 2) were prepared,
with RNA from 4 animals contributing to each RNA
pool. Hybridization to the Affymetrix GeneChip porcine
genome arrays (Affymetrix) containing 23,937 probe sets
that represent approximately 23,256 porcine transcripts
and quality assessment of the hybridization process were
performed at the Center of Excellence for Fluorescent
Bioanalytics (KFB) at the University of Regensburg for
hybridization to the Affymetrix GeneChip porcine gen-
ome arrays (Affymetrix, UK). The microarray data
related to all samples have been deposited in NCBI’s
Gene Expression Omnibus (GEO) public repository
(GEO accession number GSE22931) [18]. Data analyses
and functional interpretation of microarray data using
the bioinformatic tools from the Database for Annota-
tion, Visualization and Integrated Discovery (DAVID)
bioinformatic resource [19] were performed as described
recently in detail [17].
Quantitative real-time RT-PCR (qPCR)
Differential expression data of selected genes, FbxL3
(F-box/LRR-repeat protein 3), FbxL20 (F-box/LRR-
repeat protein 20), FbxO32 (F-box protein 32), ESRRG
(estrogen-related receptor gamma isoform 2), HECTD2
(HECT domain containing 2 isoform b), DRE1 (DRE1
protein), GPD1 (Glycerol-3-phosphate dehydrogenase),
MTTP (Microsomal triglyceride transfer protein),
ACSL3 (Long-chain-fatty-acid-CoA ligase 3), ACADSB
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(Acyl-CoA dehydrogenase, short/branched chain speci-
fic), GLUT8 (Glucose transporter type 8), GCK (Glu-
cokinase), GPAT (Glycerol-3-phosphate
acyltransferase) and USP10 (ubiquitin specific pepti-
dase 10) obtained from Affymetrix GeneChip analysis
were validated by using qPCR carried out on a Rotor-
gene 2000 system (Corbett Research, Mortlake, Austra-
lia). For qPCR all individual samples (n = 8/group)
contributing to the RNA pools for microarray analysis
were used. cDNA synthesis and qPCR analysis was
performed as described recently in detail [17]. Gene-
specific primers (Eurofins MWG Operon, Ebersberg,
Germany) were designed using Primer3 and BLAST.
Characteristics of the porcine primer pairs are listed in
Table 1. Expression values of selected genes were nor-
malized using the GeNorm normalization factor. Pro-
cedure of normalization, characteristics of gene-
specific primers and the average expression stability
ranking of the six potential reference genes in liver of
piglets were previously described in detail [20]. Relative
expression ratios are expressed as fold changes of
mRNA abundance in the carnitine group compared to
the control group.
Statistical analysis
Values presented in the text are means ± SD. Data were
analyzed by one factorial analysis of variance with diet-
ary carnitine concentration as factor using the Minitab
statistical software (Release 13, Minitab Inc., State Col-
lege, PA, USA). For statistical significant F-values (P <
0.05), means of both groups were compared by Fisher’s
multiple range test.
Results
Feed intake, final body weight and feed conversion ratio
Feed intake, final body weights and feed conversion ratio
of piglets were not different between both groups [17].
Concentration of carnitine in the liver
Pigs supplemented with L-carnitine had approximately
10-fold higher concentrations of free and total carnitine
in the liver (P < 0.05; Figure 1) than control pigs.
Table 1 Characteristics of porcine primer pairs used for validation of microarray analysis using RT-PCR
Gene symbol Primer sequence (5’-3’) GenBank
accession no.
Product size (bp)
ACADSB For:TCGTGATACCGAGGGCCTCCG XM_001926297.2 196
Rev:TCCCAGCATCTGTGCCGCAA
ACSL3 For:TCGCTGCACAGGCCTGCTTC NM_001143698.1 174
Rev:GCAGGCGCGGCACTAGAGAG
DRE1 For:CAACAACCTCCGATACTACC NP_060114.2 158
Rev:GGTCCTCCACCAATCACAAA
ESRRG For:GGATCAGATGAGTCTTCTGC XM_003357621.1 127
Rev:GGACTGGTCTTCATCCATTAT
FbxL3 For:CATAGGAGACACACCGTCTA Q9UKT7 637
Rev:GTGGGCATCATGTCTGGAAA
FbxL20 For:GTGAGGGATGTCCACTGTTG XM_003131523.2 128
Rev:CTGTGTGCAGCCTTTTAAGAA
FbxO32 For:TCACAGCTCACATCCCTGAG NM_001044588 167
Rev:GACTTGCCGACTCTCTGGAC
GCK For:GAGCGAGAGAGCAGAGCCTCAGA XM_003356680.1 221
Rev:CTGGAGCCAGCCTCCGAACG
GLUT8 For:GTGGAGCCCACCGATGCCAG EU012361.2 145
Rev:CCACGCCCTTGACGTGCAGA
GPAT For:GAATTGATCTCTCCACGTTG XM_001927875.1 257
Rev:CCTCCATGATAAAGTCGTGG
GPD1 For:GGCCGGCTGGCACACTTTGA NM_001190240.1 354
Rev:CATGGGGATGCCAAGGCGCT
HECTD2 For:GGTTTGGACAGAGGATCCAAA XM_003361201.1 130
Rev:CATTCTTGATGTTAGGGAAAAC
MTTP For:TCCCGCTGCACCAAGAGAACT NM_214185.1 151
Rev:TACCTCGGCACGGTGCATCGT
USP10 For:GTGGTGTACCAGCAGAGCT XM_003126825.2 157
Rev:GCTTGGTTTTGGTGGTGTAG
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Identification of differentially expressed genes
A total of 638 probe sets were differentially expressed
(fold change ≥ 2.0 and ≤ -2.0) between the L-carnitine
and the control group. Of these probe sets, 372 were
up-regulated by L-carnitine and 266 probe sets were
down-regulated by L-carnitine. The 15 most strongly
up-regulated and down-regulated probe sets are shown
in Table 2. Because the Affymetrix GeneChip porcine
genome array is poorly annotated, the differentially
expressed probe sets were largely annotated by the
annotation list created by Tsai et al. [21]. 563 porcine
Affymetrix probe sets were matched to human RefSeq
entries and converted into human Affymetrix probeset
IDs. Conversion of porcine Affymetrix probe set IDs
into the human probe set IDs was necessary for subse-
quent analysis by the DAVID bioinformatic resource
because this platform cannot use porcine gene informa-
tion. The distribution of signal intensities of the differ-
entially expressed probe sets of the two control and
carnitine arrays are shown in Figure 2.
Real-time RT-PCR verification of microarray data
A total of 14 genes were selected to validate the micro-
array data by the use of real-time RT-PCR. As shown in
Table 3, all tested genes were differentially expressed
with microarray analysis, however 3 genes were not sig-
nificant at an FDR P value < 0.05. The magnitude of dif-
ferential expression tended to be higher by qPCR than
those obtained from microarray analysis.
Identification of overrepresented annotation terms
563 genes identified to be differentially expressed were
used for gene-term enrichment analysis using the
DAVID Functional Annotation Chart tool. The analyses
were based on the GO category biological process. The
GO analysis assigned the 563 differentially expressed
genes to 21 biological processes (p-value < 0.01). Most
genes were allocated to the annotation terms cellular
process (357 genes), metabolic process (262 genes), and
cellular metabolic process (239 genes). The most signifi-
cantly enriched annotation terms were (top-ranked: low-
est p-values): cellular process (P = 2.0E-04), ribosome
biogenesis (P = 3.8E-04), developmental process (P =
4.0E-04), ribonucleoprotein complex biogenesis (P =
4.6E-04), cellular metabolic process (P = 6.5E-04), multi-
cellular organismal development (P = 1.5E-03), cellular
protein metabolic process (P = 1.9E-03), rRNA proces-
sing (P = 2.1E-03), and rRNA metabolic process (P =
2.8E-03). The annotation terms with the highest fold
enrichment were triglyceride metabolic process (4.5-
fold), rRNA processing (3.5-fold), ribosome biogenesis
(3.4-fold), and rRNA metabolic process (3.4-fold).
Identification of clusters of functionally related
annotation terms
To identify clusters of functionally related biological
processes we used the DAVID functional annotation
clustering tool. Clusters were ranked according to the
enrichment score for each cluster reflecting the geo-
metric mean of all the enrichment p-values (EASE
scores) of each annotation term in the cluster. The 10
top-ranked clusters showing the highest enrichment
scores are shown in Table 4. The top-ranked clusters
allocated annotation terms dealing with RNA splicing
(cluster 1), ribosomal RNA processing and non-coding
RNA processing (cluster 2), triglyceride, acylglycerol,
neutral lipid and glycerol ether metabolism (clusters 3
and 4) and regulation of glucose import and glucose
transport (cluster 5). Further clusters summarized anno-
tation terms dealing with chromosome localization
(cluster 6), posttranslational protein folding (cluster 7),
carbohydrate biosynthetic processes (cluster 8) and
organic acid metabolic processes (cluster 9), and modifi-
cation-dependent protein catabolic process and proteo-
lysis involved in cellular protein catabolic process
(cluster 10).
Discussion
In the present study we aimed to get insight into poten-
tial mechanisms of L-carnitine by applying genome-wide
transcript profiling in the liver of piglets. After feeding
carnitine supplemented diets for 3 weeks, concentrations
of free and total carnitine in the liver of the piglets were
markedly increased (approximately 10-fold) compared to
piglets fed diets without supplemental L-carnitine, indi-
cating that the supplemental L-carnitine significantly
improved the carnitine status of the piglets. As a main
result we observed that 563 genes were differentially
*
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Figure 1 Concentrations of free and total carnitine in the liver
of growing piglets fed either a control diet or a diet
supplemented with 500 mg L-carnitine per kg diet for 21 days.
Bars are mean ± SD (n = 8/group), * indicates significant differences
(P < 0.05) between groups (Fisher’s multiple range test).
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expressed by L-carnitine. This shows that supplemental
L-carnitine influences gene expression in the liver of
piglets and indicates that at least some of the biological
effects of L-carnitine are mediated by altering gene tran-
scription. To extract biological meaning from the
observed alterations in gene expression we performed
gene term enrichment analysis and functional clustering
analysis with the 563 differentially expressed genes.
Gene term enrichment analysis revealed that the most
frequent biological processes associated with L-carnitine
supplementation were dealing with metabolic processes.
This was not surprising considering that the main func-
tion of L-carnitine is to stimulate energy metabolism by
acting as shuttling molecule for long-chain fatty acids
which also enhances the metabolic flux of glucose
through the glycolytic chain. This was also confirmed by
clustering analysis showing that 6 out of the 10 top-
ranked clusters were dealing with metabolic processes.
Representative genes from one of these clusters dealing
with metabolic processes (carboxylic acid metabolic
process, oxoacid metabolic process, organic acid meta-
bolic process) encoded proteins or enzymes involved in
cellular fatty acid uptake (SLC27A6, solute carrier family
27/fatty acid transporter, member 6), fatty acid activa-
tion (ACSL3, Long-chain-fatty-acid-CoA ligase 3) and
fatty acid b-oxidation (ACADSB, Acyl-CoA dehydrogen-
ase, short/branched chain specific), and most of these
genes including SLC27A6, ACSL3 and ACADSB were
found to be significantly up-regulated by L-carnitine
supplementation by microarray analysis and confirmed
by qPCR, a more sensitive method for gene expression
analysis. Thus, our data indicate that the well-known sti-
mulatory effect of carnitine on fatty acid b-oxidation
[22,23] is at least partially mediated by stimulating the
transcription of genes involved in cellular fatty acid
uptake, fatty acid activation and b-oxidation.
Clustering analysis further revealed that L-carnitine
supplementation was significantly associated with biolo-
gical processes involved in glucose metabolism, like glu-
cose transport, conversion of glucose into glucose 6-
Table 2 The 15 most strongly up- and down-regulated genes in the liver of growing piglets fed with or without L-
carnitine
Probe set ID Gene name (Gene symbol) FC* Probe set ID Gene name (Gene symbol) FC*
Up-regulated genes Down-regulated genes
Ssc.16377.2.
A1_at
Glutathione S-transferase A3-3 (GSTA3) 129.6 Ssc.27111.1.
A1_at
Kelch-like protein 8 (KLHL8) -7.9
Ssc.18484.1.
S1_at
Hexokinase D (GCK) 26.5 Ssc.30350.1.
A1_at
Homeobox protein Meis1 (MEIS1) -6.6
Ssc.14503.1.
S1_at
Apolipoprotein A-IV precursor (ApoA4) 16.6 Ssc.15845.1.
S1_at
Mannose-binding protein C precursor (MBP-C) -5.8
Ssc.13302.1.
A1_at
Sentrin-specific protease 6 (SENP6) 13.0 Ssc.451.1.
A1_at
Insulin-like growth factor binding protein 1
precursor (IGFBP-1)
-5.8
Ssc.12965.1.
A1_at
Sprouty homolog 3 (SPRY3) 11.8 Ssc.22959.1.
S1_at
Phosphoenolpyruvate carboxykinase, cytosolic
(PCK1)
-5.7
Ssc.30459.1.
A1_at
R3H domain protein 1 (R3HDM) 11.3 Ssc.24758.1.
A1_at
estrogen-related receptor gamma isoform 2
(ESRRG)
-5.3
Ssc.25850.1.
A1_at
Telomerase-binding protein p23 (TEPB) 9.2 Ssc.21169.1.
S1_at
Synaptic vesicular amine transporter (SLC18A2) -5.1
Ssc.5327.2.
A1_at
Cytochrome P450 2J2 (CYP2J2) 9.2 Ssc.20502.1.
S1_at
Serine/threonine-protein kinase (ULK1) -5.0
Ssc.9177.1.
A1_at
SPARC related modular calcium-binding protein 1
precursor (SMOC1)
8.5 Ssc.29392.1.
A1_at
DRE1 protein (DRE1) -4.7
Ssc.30207.1.
A1_at
Ubiquitin carboxyl-terminal hydrolase 1 (USP1) 8.3 Ssc.14386.1.
A1_at
Cyclin G2 (CCNG2) -4.7
Ssc.8700.1.
A1_at
Heterogeneous nuclear ribonucleoprotein M (hnRNP
M)
8.1 Ssc.29946.1.
A1_at
T-cell lymphoma breakpoint-associated target 1
(TCBA1)
-4.2
Ssc.8308.1.
A1_at
cell adhesion molecule with homology to L1CAM
precursor (CHL1)
7.6 Ssc.28087.1.
A1_at
oxidation resistance 1 (OXR1) -4.2
Ssc.18681.1.
A1_at
Metabotropic glutamate receptor 5 precursor GRM5) 7.5 Ssc.2274.1.
A1_at
Ephrin-A1 precursor (EFNA1) -4.1
Ssc.29205.1.
A1_at
Serine/threonine-protein kinase (Nek7) 7.3 Ssc.13343.1.
A1_at
CD109 (CD109) -4.1
Ssc.18831.1.
A1_at
Glutaminase, kidney isoform, mitochondrial precursor
(GLS)
6.8 Ssc.30210.1.
A1_at
Testican-1 precursor (SPOCK) -4.0
* FC = fold change
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phosphate, and glycolysis, and hexose biosynthetic pro-
cesses, like gluconeogenesis. Representative genes
included GLUT8 (glucose transporter type 8), GCK
(Hexokinase D), GPD1 (Glycerol-3-phosphate dehydro-
genase), PCK1 (Phosphoenolpyruvate carboxykinase),
and FBP2 (Fructose-1,6-bisphosphatase isozyme 2).
Moreover, the tandem enzyme PFKFB3 (6-phospho-
fructo-2-kinase/fructose-2,6-biphosphatase 3) which is
responsible for maintaining the cellular levels of fruc-
tose-2,6-biphosphate, the most potent allosteric activator
of one of the key regulatory enzymes of glycolysis, 6-
phosphofructo-1-kinase, was also identified to be differ-
entially expressed by L-carnitine. All the genes dealing
with glucose metabolism like GLUT8, GCK and GPD1
were markedly up-regulated, at least 4-fold, by the sup-
plemental L-carnitine. These strongly up-regulation
could also observed by qPCR, supporting microarray
analysis. GCK which is the predominant hexokinase iso-
enzyme in the liver phosphorylating glucose for
Table 3 qPCR and microarray gene expression analyses
of liver tissue
Gene symbol Mean fold changes P-value
Microarray qPCR qPCR
ACADSB 2.24 4.61 0.057
ACSL3 2.15 3.48 0.001
DRE1 -4.8 -3.3 0.018
ESRRG -5.6 -12.5 0.003
FbxL20 -2.9 -14.3 0.002
FbxL3 -2.4 -4.4 0.026
FbxO32 -3.6 -3.4 0.009
GCK 26.53 1.97 0.107
GLUT8 3.55 4.55 0.018
GPAT -2.84 -1.67 0.173
GPD1 2.87 3.11 0.031
HECTD2 -2.9 -4.6 0.004
MTTP 2.14 1.75 0.031
USP10 -2.2 -3.2 0.026
array 1 array 2 array 3 array 4 
Expression level 
low high 
Genes up-regulated 
(fold change  2.0) 
by L-carnitine 
Genes down-regulated 
(fold change  -2.0) 
by L-carnitine 
control L-carnitine 
Figure 2 Heat map illustrating the level of expression for the differentially expressed genes identified as a response to feeding a diet
containing 500 mg L-carnitine per kg diet. Based on log2 transformed signal intensities the heat map was generated with software package
R (URL: http://www.R-project.org).
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Table 4 Identification of functionally related annotation groups (GO category biological process)
Cluster GO terms P-value
1 RNA splicing, via transesterification reactions 7.8E-03
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile 7.8E-03
nuclear mRNA splicing, via spliceosome 7.8E-03
2 ribosomal RNA processing 2.1E-03
ribosomal RNA metabolic process 2.8E-03
non-coding RNA processing 1.2E-01
3 triglyceride metabolic process 9.9E-03
acylglycerol metabolic process 1.7E-02
neutral lipid metabolic process 1.8E-02
glycerol ether metabolic process 2.0E-02
organic ether metabolic process 2.3E-02
4 triglyceride biosynthetic process 3.0E-02
neutral lipid biosynthetic process 5.1E-02
acylglycerol biosynthetic process 5.1E-02
glycerol ether biosynthetic process 6.0E-02
5 positive regulation of glucose import 2.9E-02
positive regulation of glucose transport 2.9E-02
regulation of glucose import 8.0E-02
regulation of glucose transport 8.6E-02
6 mitotic metaphase plate congression 2.9E-02
metaphase plate congression 4.3E-02
chromosome localization 7.6E-02
Establishment of chromosome localization 7.6E-02
7 chaperone mediated protein folding requiring cofactor 5.3E-02
’de novo’ posttranslational protein folding 5.3E-02
’de novo’ protein folding 5.3E-02
8 hexose biosynthetic process 7.1E-01
monosaccharide biosynthetic process 7.1E-01
alcohol biosynthetic process 7.1E-01
cellular carbohydrate biosynthetic process 7.1E-01
carbohydrate biosynthetic process 7.1E-01
9 carboxylic acid metabolic process 1.9E-01
oxoacid metabolic process 1.9E-01
organic acid metabolic process 2.0E-01
10 modification-dependent protein catabolic process 2.4E-01
modification-dependent macromolecule catabolic process 2.4E-01
proteolysis involved in cellular protein catabolic process 3.0E-01
cellular protein catabolic process 3.1E-01
protein catabolic process 3.7E-01
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subsequent metabolism by either glycolysis, pentose
phosphate shunt or glycogen synthesis was even induced
27-fold by L-carnitine supplementation - indicating that
L-carnitine has a dramatic effect on glucose metabolism.
Several studies have already shown that carnitine sup-
plementation increases glucose disposal and glucose oxi-
dation in animals as well as in healthy and diabetic
patients [12,24,25] due to activation of the pyruvate
dehydrogenase complex [26]. Besides allosteric regula-
tion of the activity of enzymes of the glycolytic pathway,
it is also well known that the flux through the glycolytic
pathway can be increased by induction of the rate-limit-
ing enzymes of this pathway, GCK and PFK1 (6-phos-
phofructo-1-kinase). Thus, our observations suggest that
up-regulation of genes involved in glucose uptake, glu-
cose phosphorylation and glycolysis also contributes to
increased glucose oxidation by supplemental L-carnitine.
In contrast to the genes involved in glucose metabolism,
genes involved in gluconeogenesis, like PCK1 and FBP2
were significantly down-regulated in the liver of piglets
by L-carnitine supplementation. This indicates that the
positive effect of carnitine on glucose utilization is
explained not only by stimulation of glycolysis but also
suppression of gluconeogenesis in the liver. It has been
recently shown in rats that dietary L-carnitine is capable
of restoring an increase in the activity of the gluconeo-
genic enzymes PCK1, FBP2 and glucose 6-phosphatase
caused by feeding fructose [27], which increases the
availability of the gluconeogenic substrates pyruvate, lac-
tate and glycerol. The present findings suggest that inhi-
bition of transcription of gluconeogenic genes by L-
carnitine also contributes to the suppression of gluco-
neogenesis by carnitine, which has not been demon-
strated yet. The exact reason for this effect of L-
carnitine remains to be established. However, it has
been suggested that the inhibitory effect of L-carnitine
on gluconeogenic enzyme activities is the consequence
of an improvement in the action of insulin [12,28],
which is a known repressor of expression of gluconeo-
genic genes. Supportive of this assumption is also the
identification of another annotation term cluster dealing
with positive regulation of glucose import. Considering
that insulin is the most important regulator of glucose
import, it was not surprising that genes belonging to
this cluster were involved in insulin signaling, like IRS2
(Insulin receptor substrate-2), PIK3R1 (Phosphatidylino-
sitol 3-kinase regulatory alpha subunit), and ERBB3
(Receptor protein-tyrosine kinase erbB-3 precursor).
Besides regulation by insulin action, key gluconeogenic
enzymes such as FBP2 are also known to be subject to
complex allosteric regulation. Noteworthy, one of the
allosteric inhibitors of FBP2 is fructose-2,6-biphosphate
whose cellular levels are controlled by the abovemen-
tioned tandem enzyme PFKFB3. Thus, the activity of
gluconeogenic enzymes may be influenced by L-carni-
tine through regulating the cellular availability of allos-
teric enzyme regulators as well.
Two other identified annotation term clusters were
dealing with triglyceride metabolic and triglyceride bio-
synthetic processes. Representative genes were GPAT,
which esterifies acyl-groups from acyl-ACP to the sn-1
position of glycerol-3-phosphate, an essential step in gly-
cerolipid biosynthesis, and MTTP, which catalyses the
transport of triglyceride, cholesteryl ester, and phospho-
lipid between phospholipid surfaces, and is required for
the secretion of apolipoprotein B containing lipoproteins
from the liver. In rodents, L-carnitine administration
was demonstrated to decrease liver lipids and hepatic
steatosis after administration of a high fat diet, after par-
enteral nutrition, or after alcohol intoxication [14,29,30],
with the mechanisms of action being largely unknown.
Our observations that GPAT was down-regulated
whereas MTTP and genes involved in fatty acid catabo-
lism (SLC27A6, ACSL3, ACADSB) were up-regulated by
L-carnitine supplementation in the liver of the piglets,
confirmed by qPCR. Thus, our data indicates that inhi-
bition of glycerolipid biosynthesis and stimulation of
lipoprotein secretion and fatty acid catabolism may con-
tribute to the decreased liver lipids in rodents fed L-
carnitine.
Besides metabolic processes, clustering analysis
revealed that biological processes dealing with posttran-
scriptional RNA processing (mRNA splicing, ribosomal
RNA processing, non-coding RNA processing) were sig-
nificantly associated with L-carnitine supplementation.
Noteworthy, almost all of these genes were significantly
up-regulated in the liver of the piglets by the supple-
mental L-carnitine indicating that the biological func-
tions exerted by the encoded proteins are stimulated by
L-carnitine. Posttranscriptional RNA processing, which
includes precursor-mRNA splicing, is one of the main
regulatory mechanisms of gene expression which results
in a repertoire of mRNAs, and consequently of proteins,
much larger than expected from the number of genes.
This process contributes substantially to cell-specific
and tissue-specific gene expression, and it is estimated
that over 60% of human genes are alternatively spliced
[31]. Although the exact biological meaning of the up-
regulation of genes dealing with posttranscriptional
RNA processing by L-carnitine is unclear, it is obvious
that L-carnitine supplementation has a stimulatory effect
on this important regulatory mechanism of gene expres-
sion. It is therefore possible that the alterations in gene
expression observed with L-carnitine supplementation
are mediated, at least partially, by modulating posttran-
scriptional RNA processing.
As far as the physiological relevance of the carnitine
dose (500 mg/kg) used in this study is concerned, it has
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to be noted that omnivorous humans are reported to
generally ingest 0.3-1.9 mg of carnitine per day and kg
of body weight [32]. Based on a daily feed consumption
of approximately 500 g per day and a final body weight
of the piglets of about 17 kg this relates to 15 mg of
carnitine/kg body weight indicating that the carnitine
dose applied to the piglets was at least 8-fold higher
than achieved in humans by a normal diet. However,
when compared to several clinical trials in which free
carnitine was supplemented up to 3 g per day and sub-
ject [33-35], which relates to 40 mg carnitine/kg body
weight for a human weighing 70 kg, the dose applied in
our study can be regarded as low. Therefore, the benefi-
cial effects of carnitine supplementation on several
metabolic parameters observed in the abovementioned
clinical trials may be at least partially explained by the
alterations in gene expression found in our pig model.
In several clinical trials, carnitine supplementation was
shown to improve glucose homeostasis and insulin sen-
sitivity in obese, insulin resistant and diabetic subjects
[36,37]. Due to theses effects carnitine supplementation
has gained significant attention as a tool for the treat-
ment or prevention of insulin resistance and type 2 dia-
betes mellitus [38]. The improvement of glucose
tolerance has been explained by a normalization of
mitochondrial fuel metabolism, which is perturbed dur-
ing insulin resistance due to an intracellular accumula-
tion of acyl-CoA derivatives. Recent evidence indicates
that carnitine supplementation corrects these mitochon-
drial perturbations through an increased efflux of acyl-
carnitine out of mitochondria and cells into the blood
[39]. Based on our transcriptomic data it cannot be eval-
uated whether or not acyl-carnitine efflux and mito-
chondrial function was stimulated by carnitine in the
piglets of this study. However, since convincing evidence
from both human and animal studies suggests that car-
nitine lowers “mitochondrial stress” and improves mito-
chondrial function, in particular in the face of energy
surplus, we suggest that carnitine also improved mito-
chondrial function in our pig model.
In conclusion, results of the present study show that
supplemental L-carnitine influences gene expression in
the liver of growing piglets. Our data suggest that L-
carnitine supplementation has beneficial effects on
lipid and glucose homeostasis by inducing genes
involved in fatty acid catabolism and glycolysis and
repressing genes involved in gluconeogenesis. In addi-
tion, the data indicate that the effects of L-carnitine on
transcription of glycolytic and gluconeogenic genes are
mediated by potentiating the action of insulin and that
at least some of the alterations in gene expression
observed with L-carnitine supplementation are
mediated by modulating posttranscriptional RNA pro-
cessing. Regarding the strong similarities between pigs
and humans with regard to metabolism, our data
obtained in piglets can be considered as relevant for
humans. Future studies employing both, transcrip-
tomics and metabolomics are required to confirm a
correlation between alterations in gene expression and
modulation of carbon fluxes through metabolic
pathways.
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